Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID vaccine + IMT504
- Development stage
- Preclinical
- Lead developer
- Curative Biotechnology
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Curative Biotechnology is developing a next-generation COVID-19 vaccine specifically designed for kidney failure patients, including those on dialysis or who have received a kidney transplant. This population often exhibits impaired immune responses to standard mRNA vaccines. The vaccine candidate combines a proprietary protein-based antigen with IMT504, a novel patented immunotherapy and adjuvant licensed from Mid-Atlantic BioTherapeutics (MABT). IMT504 is a non-CpG oligodeoxynucleotide that acts as an immunostimulant to boost the immune response in immunocompromised individuals. The program is currently in the preclinical stage, with the company working toward an Investigational New Drug (IND) application for Phase I/II clinical trials.
- Other names
- COVID Vaccine with IMT504 Adjuvant
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on COVID vaccine + IMT504.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID vaccine + IMT504.